DDInter1042 DDInter809
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037]
Gatifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Gatifloxacin {u} (Compound) binds {v} (Gene) ALB
Gatifloxacin {u} (Compound) upregulates {v} (Gene) ABCC5
Gatifloxacin {u} (Compound) downregulates {v} (Gene) RPS4Y1
Gatifloxacin {u} (Compound) causes {v} (Side Effect) Gastritis
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mitomycin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ferrous fumarate
Gatifloxacin (Compound) resembles Lomefloxacin (Compound)
Gatifloxacin (Compound) resembles Sparfloxacin (Compound)
Gatifloxacin (Compound) binds ALB (Gene)
Gatifloxacin (Compound) upregulates ABCC5 (Gene)
Gatifloxacin (Compound) downregulates RPS4Y1 (Gene)
Gatifloxacin (Compound) causes Gastritis (Side Effect)
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Mitomycin
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate